Skip to main content

GOLDMAN SACHS GROUP INC

Position in QNCX — Quince Therapeutics, Inc.

CIK 886982 NEW YORK, NY

Position in QNCX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$324,492
-$153,571,158 QoQ
Shares Held
16,064
-93.0% QoQ
Ownership
0.099%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#20
of 46 holders
Holding Since
Jun 2020
12 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in QNCX Over Time

Shares Held

Position Value (USD)

Derivatives in QNCX

reported options exposure · as of Sep 30, 2021
CallValue
$91,660,000
CallShares
5,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $10,294,260,512 across 365 Biotechnology names. QNCX ranks #308 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in QNCX

Export CSV
14 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $324,492 16,064
2025-12-31 $153,895,650 229,695
2022-09-30 $7,873,068 29,598
2022-06-30 $39,229,176 88,354
2022-03-31 $76,262,038 61,601
2021-12-31 $311,163,768 123,282
2021-09-30 $748,697,212 40,841
2021-09-30 $91,660,000 5,000
2021-06-30 $53,000,000 5,000
2021-06-30 $260,293,600 24,556
2021-03-31 $149,012,874 20,679
2020-12-31 $269,404,884 48,489
2020-09-30 $380,880,000 38,088
2020-06-30 $358,047,160 38,666